...
首页> 外文期刊>The Journal of Allergy and Clinical Immunology >Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers.
【24h】

Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers.

机译:与单独的吸入器相比,从单个吸入器吸入的丙酸氟替卡松和沙美特罗之间增强的协同作用。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The coadministration of long-acting inhaled beta(2)-agonists and inhaled corticosteroids is the most effective treatment for persistent asthma. OBJECTIVE: This meta-analysis aimed to determine the efficacy of fluticasone propionate and salmeterol inhaled from a single inhaler (combination therapy) or from separate inhalers (concurrent therapy). METHODS: Four similarly designed double-blind studies individually confirmed equivalence between combination and concurrent therapy on the basis of the primary efficacy measure (morning peak expiratory flow [PEF]). Each study showed a consistent trend in favor of combination therapy. Individual patient data from these studies were combined to provide overall estimates of treatment effect for morning PEF and other efficacy measures. RESULTS: Fixed-effects meta-analysis showed a significant advantage for combination therapy compared with concurrent therapy in morning PEF (mean difference between groups in change from baseline over 12 weeks of 5.4 L/min; P =.006; 95% CI = 1.5-9.2). Logistic regression analysis showed that the odds of achieving a greater than 15 or greater than 30 L/min improvement with combination therapy were increased by approximately 40% compared with those after concurrent therapy (15 L/min: odds ratio = 1.42, P =.008, 95% CI = 1.1-1.8; 30 L/min: odds ratio = 1.40, P =.006, 95% CI = 1.1-1.8), representing an additional 7% to 9% and 5% to 14% more patients, respectively, on combination therapy responding compared with those on concurrent therapy. CONCLUSION: The meta-analysis indicates that the fluticasone propionate plus salmeterol combination offers the potential for increased clinical efficacy over concurrent use of the same doses of the same 2 drugs. After administration from a single inhaler, fluticasone propionate and salmeterol might codeposit in the airways. It is hypothesized that this codeposition offers an increased opportunity for synergistic interaction to occur.
机译:背景:长效吸入性β(2)激动剂和吸入性糖皮质激素的共同给药是持续性哮喘最有效的治疗方法。目的:本荟萃分析旨在确定单支吸入器(联合治疗)或分开吸入器(并行治疗)吸入丙酸氟替卡松和沙美特罗的疗效。方法:四项类似设计的双盲研究在主要疗效指标(早晨呼气峰流量[PEF])的基础上分别确认了联合治疗与同时治疗的等效性。每项研究均显示出一致的趋势,倾向于联合治疗。将这些研究中的单个患者数据进行合并,以提供早晨PEF的治疗效果和其他功效指标的总体估计。结果:固定效果荟萃分析显示,与早晨PEF同期治疗相比,联合治疗具有显着优势(12周内两组基线之间变化的平均差异为5.4 L / min; P = .006; 95%CI = 1.5 -9.2)。 Logistic回归分析显示,与同时疗法相比,联合疗法达到15 L / min以上或30 L / min以上改善的几率增加了约40%(15 L / min:优势比= 1.42,P =。 008,95%CI = 1.1-1.8; 30 L / min:优势比= 1.40,P = .006,95%CI = 1.1-1.8),分别多了7%至9%和5%至14%的患者与同时治疗相比,联合治疗分别有反应。结论:荟萃分析表明丙酸氟替卡松加沙美特罗的组合提供了比同时使用相同剂量的相同两种药物增加临床疗效的潜力。从单个吸入器中给药后,丙酸氟替卡松和沙美特罗可能会在呼吸道中共沉积。假设该共存为协同相互作用的发生提供了更多的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号